immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio

New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010

TUEBINGEN, Germany, September 21, 2010 - immatics biotechnologies GmbH, a biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer,
announced today that it has raised EUR53.8million in a Series C financing
round. The new funds will allow the Company to finance the ongoing
development of immatics' existing pipeline of advanced therapeutic cancer
vaccine candidates. In particular, it allows the company to perform a Phase
III pivotal trial of its lead product IMA901 which in data reported in June
at ASCO, demonstrated the potential to confer an overall survival benefit in
patients with advanced renal cell carcinoma (RCC).

The Series C round was supported by both existing and new
investors. Approximately half of the funds came from dievini Hopp Biotech
holding, Wellington Partners and other existing shareholders, the other half
coming from new investors MIG-advised funds and AT Impf GmbH. Upon the
completion of the round Dr. Matthias Kromayer from MIG AG will join the
immatics board. dievini Hopp BioTech holding remains immatics' largest
shareholder following this financing.

With the new funds, immatics will start a Phase III pivotal
clinical trial with its lead cancer vaccine IMA901 later this year. IMA901 is
a rationally designed cancer vaccine comprised of 10 different
tumor-associated peptides (TUMAPs) that are frequently found to be
over-expressed in the majority of patients suffering from renal cell
carcinoma. The trial design builds on insights gained from the Phase II study
and input from key opinion leaders and regulatory agencies. The trial will be
a randomized, controlled study that will evaluate IMA901 in renal cell
carcinoma patients in combination with standard of care against standard of
care alone in a first-line setting. The primary end point of the trial will
be overall survival and the first results are expected towards the end of
2013.

immatics will also continue the clinical development of
IMA910, another therapeutic vaccine that is currently being evaluated in a
Phase II clinical study in approx. 90 patients with advanced colorectal
cancer. The Company's third clinical project, IMA950 is in preparation for
two Phase I studies in patients with glioblastoma in collaboration with
Cancer Research UK and with the National Cancer Institute in the US.
Furthermore, the Company will seek to move IMA941 for treatment of gastric
cancer patients in East Asia into the clinic and will continue to expand and
further improve its XPRESIDENT(TM) antigen discovery platform.

immatics' pipeline of advanced therapeutic vaccines has been
developed using the unique XPRESIDENT(TM) technology. This platform has the
ability to identify specific tumor associated peptides (TUMAPS) related to
any cancer type in a fast and reliable manner. This allows the company to
generate better cancer vaccines rapidly, to patent them and to move new
vaccine candidates into the clinic in less than 24 months. Additionally,
immatics' XPRESIDENT(TM) technology can be used to identify disease
associated peptides in areas beyond cancer.

Paul Higham, CEO of immatics said: "Attracting such financial
backing from leading European biotech investors demonstrates a strong belief
in our company and development programs. With this financing now in place, we
can fully focus on the further clinical development of our three leading
cancer vaccine programs. Importantly, we are now able to move our lead
program, IMA901 in renal cell carcinoma into a Phase III pivotal study by the
end of this year, a key step in bringing promising novel therapeutic vaccines
to cancer patients. This Series C financing will also allow us to invest in
developing our other vaccine candidates and to explore further the potential
of our underlying XPRESIDENT(TM) technology platform."

Dr. Matthias Kromayer from MIG AG commented: "It is
increasingly clear that therapeutic vaccines have the potential to
revolutionize the treatment of cancer. We were very impressed by the Phase II
results immatics generated with IMA901 and saw in the management team and in
their plans, a clear route to a high increase in the value of the Company.
With the Company's approach to rationally designed vaccines, we believe
immatics is very well placed to become a leader in this fast emerging area
and make a real impact on the lives of cancer patients."

Prof. Christof Hettich from dievini Hopp BioTech holding
commented: "We are pleased to be able to continue to support immatics. We are
convinced of the immatics approach to cancer vaccines and we also believe
that the management team will be able to deliver on the compelling plan they
have developed and generate significant value for all shareholders."

Prof. Erich Schlick from Wellington Partners commented:
"Wellington's continuing support of immatics is based on a strong belief in
the clinical relevance of peptide based cancer vaccines and the excellent
performance of management since our initial investment."

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical
company developing advanced therapeutic vaccines that are active against
cancer. immatics' lead product, IMA901 has completed a successful Phase II
trial in renal cell carcinoma. immatics' pipeline also includes IMA910, in
Phase II for colorectal cancer, and IMA950 which is being developed for
glioma.

immatics' technology platform rapidly generates defined
therapeutic cancer vaccines which are based on multiple tumor-associated
peptides (TUMAPs) with the ability to specifically stimulate the immune
system against cancer cells. These vaccines - comprising multiple peptides
confirmed to be naturally presented by real tumor tissue - offer the prospect
of greater effectiveness than existing cancer vaccine approaches combined
with fewer side effects. immatics' products are 'drug like' with stable,
off-the-shelf formulations and robust easily scalable manufacturing.

immatics is based in Tuebingen and Munich, Germany, and has
raised more than EUR100 million (US$130million) in private equity in three
financing rounds.

About AT Impf GmbH

AT Impf GmbH is a wholly owned company of Dr. Andreas and Dr.
Thomas Strungmann. The company holds several Biotech-Investments and is
managed by the Family Office of the Strungmann-brothers, through which they
offer their know-how and strategic support.

About dievini Hopp BioTech holding GmbH & Co. KG

dievini Hopp BioTech holding is dedicated to the support and
coaching of the life cycle management of companies and organizations in Life
and Health Sciences. A team of experts in medicine, science, finance, legal
and entrepreneurship are supporting dievini's investments in the companies'
corporate and business development. www.dievini.com

About MIG Verwaltungs AG

MIG Verwaltungs AG (MIG) provides management services for MIG
funds which are public venture capital funds. In total, MIG has more than 500
million Euros under management and provides venture capital to young,
non-listed companies located in Germany, Austria and Switzerland. The
investment strategy and the assistance given to portfolio companies are
greatly determined by the entrepreneurial experience of MIG's team. MIG has
been living and practicing entrepreneurship in all its facets. As a
consequence MIG defines their role not merely as being an investor but also
as a responsible, competent partner. www.mig.ag

About Wellington Partners

Wellington Partners is one of the most successful pan-European
venture capital firms. With some 800 million Euros under management and
offices in London, Munich, Palo Alto and Zurich, the firm invests into
companies throughout Europe that have the potential to become global leaders,
in the areas of Digital Media, Cleantech, Electronics, Software and Life
Sciences.

Since 1998, Wellington Partners has invested in more than 100
companies in Europe and Israel, including now publicly traded Actelion and
XING and successful privately held companies like Alando (acquired by eBay),
Ciao (acquired by Microsoft) and ImmobilienScout24 (acquired by Deutsche
Telekom). www.wellington-partners.com

    For additional information on immatics please visit
    www.immatics.com or contact:

    Paul Higham, CEO
    Katrin Eckert, Assistant to the Management
    immatics biotechnologies GmbH
    Phone: +49-7071-5397-110
    E-mail: media@immatics.com

    Citigate Dewe Rogerson
    David Dible / Chris Gardner / Amber Bielecka
    Phone: +44-207-638-9571
    E-mail: david.dible@citigatedr.co.uk

Contact: Paul Higham, CEO, Katrin Eckert, Assistant to the Management, immatics biotechnologies GmbH, Phone: +49-7071-5397-110, E-mail: media at immatics.com . Citigate Dewe Rogerson, David Dible / Chris Gardner / Amber Bielecka, Phone: +44-207-638-9571, E-mail: david.dible at citigatedr.co.uk .